

Appendix 3Y

Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available.
Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Antisense Therapeutics Limited (ASX:ANP)
ABN:	41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr Robert W Moses
Date of Last Notice:	9 th January 2017

Part 1 – Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct		
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A		
Date of change	9 th February 2017		
No. of securities held prior to change		Shares	Options
	Direct	4,000,000	2,126,889
	Indirect	-	
	Total	4,000,000	2,126,889
Class	Ordinary Shares		
Number acquired		Shares	Options
	Direct	600,000	-
	Indirect	-	-
	Total	600,000	
Number disposed		Shares	Options
ANPO Options lapsed (31 January 2017)	Direct	-	708,001
	Indirect	-	-
	Total	-	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$22,800 (3.8 cents per share) Nil consideration received for lapsed options													
No. of securities held after change	<table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>4,600,000</td> <td>1,418,888</td> </tr> <tr> <td>Indirect</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>4,600,000</td> <td>1,418,888</td> </tr> </tbody> </table>			Shares	Options	Direct	4,600,000	1,418,888	Indirect	-	-	Total	4,600,000	1,418,888
	Shares	Options												
Direct	4,600,000	1,418,888												
Indirect	-	-												
Total	4,600,000	1,418,888												
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off market trade – see company announcement dated 8 th February 2017													

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A



The CFO Solution

13th February 2017

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available.
Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Antisense Therapeutics Limited (ASX:ANP)
ABN:	41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr Mark Diamond
Date of Last Notice:	21 st December 2016

Part 1 – Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct		
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-		
Date of change	9 February 2017		
No. of securities held prior to change		Shares	Options
	Direct	1,457,914	993,961
	Indirect	-	
	Total	1,457,914	993,961
Class	Ordinary Shares		
Number acquired		Shares	Options
	Direct	263,158	-
	Indirect	-	-
	Total	263,158	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed *ANPO Options lapsed (31 January 2017)		Shares	Options
	Direct	-	351,189*
	Indirect	-	-
	Total	-	351,189
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$10,000 (3.8 cents per share) Nil consideration received for lapsed options		
No. of securities held after change		Shares	Options
	Direct	1,721,072	642,772
	Indirect	-	-
	Total	1,721,072	642,772
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off market trade – see company announcement dated 8 th February 2017		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A



13th February 2017

+ See chapter 19 for defined terms.